[Treatment of chronic hepatitis C in HIV-infected patients]. / Traitement de l'hépatite chronique C chez les patients co-infectés VHC-VIH.
Gastroenterol Clin Biol
; 33 Suppl 2: S97-S103, 2009 Mar.
Article
em Fr
| MEDLINE
| ID: mdl-19375043
ABSTRACT
Since the pivotal trials conducted over the last few years which have used the combination of pegylated interferon along with fixed low doses (800 mg/day) of ribavirin and have provided treatment for 12 months, regardless the kinetics of hepatitis C virus (HCV) viral load during therapy, great progress has been made in the treatment of chronic hepatitis C in HIV-infected patients. Results approaching those seen in HCV-monoinfected patients can be obtained with optimal dosages of ribavirin, extension of treatment beyond 48 weeks in the absence of rapid virologic response and/or in patients older than 40 years, with severe fibrosis (METAVIR score F3 or F4) and/or with high HCV viral load and with a better management of HIV treatment in order to avoid a negative interaction between HCV and HIV therapies (interaction between abacavir and ribavirin) and to improve the tolerance of HCV therapy (Didanosine should never be used with ribavirin, Zidovudine and Stavudine should be avoided when possible with ribavirin).
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Polietilenoglicóis
/
Ribavirina
/
Infecções por HIV
/
Interferon-alfa
/
Infecções Oportunistas Relacionadas com a AIDS
/
Hepatite C Crônica
Tipo de estudo:
Etiology_studies
/
Guideline
/
Risk_factors_studies
Limite:
Humans
Idioma:
Fr
Revista:
Gastroenterol Clin Biol
Ano de publicação:
2009
Tipo de documento:
Article